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Abstract: In the present study, natural phaeosphaeride A (PPA) derivatives are synthesized. Antitumor studies are carried out on the PC3, K562, HCT-116, THP-1, MCF-7, A549, NCI-H929, Jurkat,
and RPMI8226 tumor cell lines, and on the human embryonic kidney (HEK293) cell line. All the
compounds synthesized turned out to have better efficacy than PPA towards the tumor cell lines
listed. Among them, three compounds exhibited an ability to overcome the drug resistance of
tumor cells associated with the overexpression of the P-glycoprotein by modulating the work of this
transporter. Luminex xMAP technology was used to assess the effect of five synthesized compounds
on the activation of intracellular kinase cascades in A431 cells. MILLIPLEX MAP Multi-Pathway
Magnetic Bead 9-Plex was used, which allowed for the simultaneous detection of the following
nine phosphorylated protein markers of the main intracellular signaling pathways: a universal
transcription factor that controls the expression of immune-response genes, apoptosis and cell cycle
NFκB (pS536); cAMP-dependent transcription factor (CREB (pS133); mitogen-activated kinase p38
(pT180/pY182); stress-activated protein kinase JNK (pT183/pY185); ribosomal SK; transcription
factors STAT3 (pS727) and STAT5A/B (pY694/699); protein kinase B (Akt) (pS473); and kinase
regulated by extracellular signals ERK1/2 (pT185/pY187). The effect of various concentrations of PPA
derivatives on the cell culture was studied using xCelligence RTCA equipment. The compounds were
found to modulate JNK, ERK1/2, and p38 signaling pathways. The set of activated kinase cascades
suggests that oxidative stress is the main probable mechanism of the toxic action of PPA derivatives.

iations.
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1. Introduction
Multiple drug resistance (MDR) of tumor cells is a major obstacle for the chemotherapy
of malignant neoplasms. MDR is a system for protecting cells simultaneously from many
drugs that differ in their chemical structure and mechanism of action on the cells [1].
Among the known molecular causes of drug resistance in human tumors is the currently

Pharmaceuticals 2022, 15, 395. https://doi.org/10.3390/ph15040395

https://www.mdpi.com/journal/pharmaceuticals

Pharmaceuticals 2022, 15, 395

2 of 15

well-characterized mechanism of the increased activity of the ABC family protein (ATPbinding cassette) P-glycoprotein (ABCB1, hereafter P-gp), encoded by the ABCB1 (MDR1)
gene [2].
One of the characteristic features of P-gp is its broad substrate specificity, ranging from
small molecules, such as organic cations, carbohydrates, amino acids, and some antibiotics,
to macromolecules, such as polysaccharides and proteins [3]. Usually, P-gp substrates are
weakly amphipathic or relatively hydrophobic, and most of them contain aromatic rings
and a positively charged tertiary nitrogen atom in their structure [3].
Basal expression levels of ABC transporters in tumors vary significantly, depending
on the cell type. Thus, tumors of the intestine and ureters, and hepatocellular carcinoma,
are characterized by a high constitutive expression of P-gp and (or) the ABCB1 gene [4].
However, it has become clear from clinical practice that the basal level of ABCB1 gene
expression may not always be a diagnostic sign of tumor resistance. In acute myelocytic
leukemia, small cell lung cancer, and in breast and ovarian tumors, the initial level of ABCB1
expression is usually low. However, after chemotherapy, an increase in P-gp expression has
been shown and the appearance of resistance has been observed. Thus, P-gp expression
was found in 14% of patients with breast tumors during the initial examination, while, after
chemotherapy, it increased up to 43% [5].
P-gp exports a wide range of structurally and mechanically unrelated chemotherapeutic agents, covering almost the whole spectrum of anticancer drugs approved for clinical use, including vinca alkaloids, podophyllotoxins, taxanes, tyrosine kinase inhibitors,
camptothecin analogs, antibiotics, anthracyclines, antimetlotoxins and epiodofenes, and
anthrodophylenes. Therefore, over the past several decades, numerous attempts have
been made to solve the problem of MDR caused by proteins of the ABC transporter family
using inhibitors of these proteins [6]. Inhibitors can modulate P-gp function by breaking
ATP hydrolysis, changing P-gp expression, or by reversible/irreversible competition for
the binding site. One of the most common mechanisms demonstrated by classical P-gp
inhibitors is the competition with drug binding sites.
To date, there are three generations of P-gp inhibitors, some of which have been tested
in clinical trials, but unfortunately most have failed [7] due to the nonspecific toxicity of the
inhibitor, an increase in the toxicity of the main drug, and an increase in the toxicity of a
co-administered drug in healthy tissues by inhibiting the basic activity of P-gp. Hence, there
is an urgent need to identify new, more effective, and non-toxic P-gp inhibitors without
drug interactions [8].
Recently, compounds obtained from natural products were viewed as promising ABC
transporter modulators for MDR control. Flavonoids and terpenoids have been widely
studied as mono- or double modulators of transporter proteins [9].
Phaeosphaeride A (PPA) is a natural product that possesses anti-tumor properties. PPA
was first isolated from the endophytic fungus FA39 (Phaeosphaeria avenaria) by Clardi et al.
in 2006, and was reported to inhibit STAT3/DNA binding with an IC50 value of 0.61 mM [3].
In this case, PPA was chosen for its ability to inhibit the signaling pathway of the signal
transducer and transcription activator 3 (STAT3). The stereochemical configuration of
this natural product was established by the complete synthesis of ent-phaeosphaeride A
and PPA [10] and by using X-ray diffraction [11]. Aberrant activity of the STAT3 protein
was found in many types of tumors, including breast, ovarian, kidney, prostate, and lung
cancers, as well as in some leukemias and multiple myeloma [12,13]. STAT3 promotes
oncogenesis by regulating the expression of various target genes, including cell cycle
regulators, angiogenic factors, and anti-apoptotic genes [12,14–17]. Various approaches to
inhibiting the STAT3 protein have been developed, and amongst its promising inhibitors is
PPA and its derivatives [12,13,17–21].
PPA derivatives are novel little-studied compounds, and therefore the study of their
effect on the signaling pathways of cell transduction, the activity of which is associated with
the survival and resistance of tumor cells, is an important area. The key signaling pathways
associated with proliferation, apoptosis, differentiation, and also underlying the emergence
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Table 1. IC50 value (µM) of compounds for adhesive tumor cultures of epithelial origin.

Etoposide
1
2
5
8
9
10

HCT-116

MCF-7

PC3

A549

HEK293

21.0 ± 9.9
7.6 ± 0.9
4.2 ± 0.2
12.0 ± 0.9
7.5 ± 1.0
3.9 ± 0.1
not active

8.9 ± 2.3
3.9 ± 0.8
3.0 ± 0.8
7.4 ± 0.5
1.8 ± 0.4
2.9 ± 1.0
49.0 ± 5.3

27.1 ± 3.2
7.6 ± 0.9
5.9 ± 3.0
9.4 ± 1.0
3.3 ± 0.6
7.8 ± 0.1
not active

65.3 ± 5.2
14.0 ± 0.1
9.6 ± 2.1
23.4 ± 2.3
16.3 ± 0.9
8.9 ± 0.2
not active

2.0 ± 0.5
5.1 ± 0.7
4.2 ± 0.3
8.2 ± 0.9
3.8 ± 0.2
3.8 ± 0.4
41.0 ± 2.1

Table 2. IC50 value (µM) of compounds for suspension cultures derived from hematopoietic tumors.

Etoposide
1
2
5
8
9
10

NCI-H929

THP-1

K562

RPMI8226

Jurkat

1.4 ± 0.5
0.7 ± 0.2
0.5 ± 0.1
2.9 ± 0.3
0.9 ± 0.3
0.6 ± 0.2
5.6 ± 0.7

1.8 ± 0.2
1.5 ± 0.4
0.9 ± 0.3
8.2 ± 0.6
1.8 ± 0.2
1.7 ± 0.2
42.0 ± 5.2

5.5 ± 3.0
3.8 ± 0.6
2.4 ± 0.7
6.5 ± 0.5
3.4 ± 0.3
3.7 ± 0.5
45.0 ± 5.4

7.2 ± 1.9
1.6 ± 0.3
1.6 ± 0.5
6.3 ± 0.3
1.5 ± 0.4
1.8 ± 0.2
51.0 ± 0.2

0.9 ± 0.3
1.5 ± 0.4
1.1 ± 0.1
3.7 ± 0.2
1.0 ± 0.3
1.3 ± 0.4
94.0 ± 22.6

Assessment of the Cytotoxicity Level in Primary Cultures of Soft Tissue Sarcomas
Furthermore, the cytotoxicity level of the several most active compounds in the primary cultures of soft tissue sarcomas (SMTs) was assessed [28], i.e., cultures obtained from
samples of SMT tumors, and passed several times outside the body. It is believed that such
cultures have a molecular profile that corresponds more with cells from the human body,
in comparison with that of stable cultures of tumor cells [29] (Table 3).
Table 3. IC50 value (µM) of compounds for primary cultures of soft tissue sarcomas.
CMT № 1

CMT № 2

CMT № 3

Histological Subtype

Extraskeletal
Ewing’s Sarcoma

Malignant
Schwannoma

Epithelial Sarcoma
(Metastasis)

1
2
8
9

2.6 ± 1.1
1.6 ± 0.7
3.9 ± 0.8
2.9 ± 1.1

2.5 ± 0.9
1.9 ± 0.5
2.3 ± 0.8
4.1 ± 1.1

4.8 ± 0.9
7.8 ± 0.6
4.8 ± 0.5
13 ± 0.9

The synthesized compounds have cytotoxic activity against primary cultures of SMT
of various histological forms.
Overcoming Drug Resistance of Tumor Cells
At the next stage, the cytotoxic activity of compounds 1, 2, and 9 (Scheme 2) was
investigated on several pairs of cell lines that differ in the expression of P-gp and the method
by which they were obtained. K562/i-S9 cells are the result of the ABCB1 transfection into
K562 cells, which increases P-gp expression, but should not seriously affect other signaling
pathways that could lead to drug resistance. K562/i-S9_Dox cells were obtained from
K562/i-S9 by selection with low concentrations of doxorubicin to increase P-gp expression.
Subline HBL-100/Dox is a derivative of HBL-100 cells, obtained by long-term selection
with increasing concentrations of doxorubicin, which led not only to an increase in P-gp
expression, but also to a change in the signaling pathways in this subline. Cells of the
K562/i-S9_Dox subline express the highest level of P-gp: 94.7% ± 2.3 (p < 0.0001 relative
to K562, and p = 0.04 relative to K562/i-S9). In cells of the K562/i-S9 line, the expression
of P-gp is 80% ± 8.2 (p < 0.0001 relative to K562). At 0.7% ± 0.5, P-gp is practically not
expressed in K562 cells (Figure 1).
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Doxorubicin, µM

0.36 ± 0.17
3.9 ± 1.6
10.3 ± 1.2
Table 4. IC50 value of compounds
on
sensitive
K562
cells
and
resistant
versions
K562/i-S9
and± 0.8
1, µM
3.8 ± 0.6
2.4 ± 0.6
3.1
Compound
K562
K562/i-S9
K562/i-S9_Dox
K562/i-S9_Dox.
2, µM
2.4 ± 0.7
1.6 ± 0.5
2.4 ± 0.9
Doxorubicin, µM
0.36 ± 0.17
3.9 ± 1.6
10.3 ± 1.2
9, µMК562
3.7 ± 0.5
2.8 ± 0.6
3.3 ± 0.6
Compound
К562/i-S9
К562/i-S9_Dox
1, µM

3.8 ± 0.6

2.4 ± 0.6

3.1 ± 0.8

Doxorubicin, µM
3.9 ± 1.6 1.6 ± 0.5
10.3 ± 1.22.4 ± 0.9
2, µM0.36 ± 0.17
2.4 ± 0.7
1, µM
2.4 ± 0.6 2.8 ± 0.6
3.1 ± 0.83.3 ± 0.6
9, µM 3.8 ± 0.6
3.7 ± 0.5
2, µM
2.4 ± 0.7
1.6 ± 0.5
2.4 ± 0.9
9, µM
3.7 ±were
0.5 obtained for the2.8
± 0.6 and HBL-100/Dox
3.3 ±line
0.6 pairs (Table 5).
Similar results
HBL-100
HBL-100/Dox cells were 556 times and 23 times more resistant to doxorubicin and etoposide, respectively (p < 0.0001), but there was no difference in resistance to 1 and 2 between
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cells. Only for 9 is there a tendency towards a slightly higher resistance of HBL-100/Dox
cells compared to HBL-100.
Table 5. IC50 value of compounds for sensitive HBL-100 cells and resistant version HBL-100/Dox.
Compound

HBL-100

HBL-100/Dox

p Value

Doxorubicin, µM

0.23 ± 0.03

128.0 ± 7.4

p < 0.0001

Etoposide, µM

4.7 ± 0.9

111.3 ± 8.3

p < 0.0001

1, µM

6.2 ± 0.8

7.6 ± 0.6

0.26

2, µM

4.9 ± 1.0

6.6 ± 1.2

0.31

9, µM

6.5 ± 0.8

8.4 ± 0.4

0.06

Thus, the compounds studied in this work overcome drug resistance associated with
P-gp overexpression, which has been shown in several pairs of sensitive and resistant
tumor cell lines.
Interaction of the Obtained Compounds with the P-Glycoprotein
We investigated the potential interaction of some synthesized compounds with P-gp
(Table 6, Figure 2) in classical experiments on the release of rhodamine Rd123 (fluorescent
agent, P-gp substrate). After 20 min of incubation with Rd123, almost 100% of the cells of
the K562/i-S9_Dox line are stained, but after removing Rd123 from the mixture, after about
30 min, the number of luminous cells drops to 17%, because P-gp removes Rd123 from the
cells. However, the addition of verapamil inhibits this process, and 90% of the cells remain
luminous. All the investigated compounds act in the same direction, while substances 2
and 9 act with an efficiency similar to that of verapamil: the number of luminous cells is 82%
and 80%, respectively. Compound 1 has a weaker interaction with P-gp than verapamil;
the number of luminous cells is 73%.
Table 6. Release of Rd123 from K562/i-S9_Dox cells under the influence of the investigated compounds.
Sample

% Luminous
Cells

Rh 123 entry

99.8 ± 0.3

Rh123 release

17.1 ± 6.6

Rh 123 (release) + verapamil

Compounds vs.
Release of Rh123

89.7 ± 8.1

p < 0.0001

Compounds vs. Verapamil’s
Rh 123 (Release)

Rh123 (release) + 1

73.4 ± 6.7

p < 0.0001

0.025

Rh 123 (release) + 2

82.4 ± 3.0

p < 0.0001

0.13

Rh 123 (release) + 9

80.2 ± 6.2

p < 0.0001

0.08

The experiments show that the synthesized compounds modulate the activity of
P-gp, significantly reducing it, with approximately the same efficiency as the classical
inhibitor verapamil.
2.2.2. Influence of Phaeosphaeride A Derivatives on the Key Signaling Pathways
LuminexxMAP technology was used to assess the effects of compounds 1, 2, 5, 9,
10 and PPA (the most active and the most inactive among all PPA derivatives) on the
activation of intracellular kinase cascades in A431 cells. A431 cells are characterized by a
high inducibility of transcription factors STAT3 and STAT5. In turn, phaeosphaeride A and
its derivatives are probably inhibitors of the STAT3 gene [14]. Therefore, the A431 cell line
was chosen as a model for searching for possible targets for the action of phaeosphaeride A
derivatives. Table 7 presents IC50 data for phaeosphaeride A derivatives on A431 cells.
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of compounds on cells and compares their effectiveness. In this experiment, the signaling
pathways Akt (pSer473), p70S6K (pThr412), NFkB (p65-pSer536), and CREB (pSer133) were
not activated (Table 8). The stress-activated signaling pathways ERK/MAP kinase 1/2
(pThr185/pTyr187), JNK (pThr183/pTyr185), and p38 (pThr180/pTyr182) were activated
for these compounds.
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Table 8. Influence of phaeosphaeride A derivatives on the level of protein active forms of key kinase cascades (the phosphorylation site is marked) in lysates of A431
cells, fluorescence intensity, rel. units (M ± mx).
Analyte (Fluorescence Intensity, Rel. Units (M ± mx))
1
2

Cmpd

Akt
(pSer473)

CREB
(pSer133)

ERK
(pThr185/pTyr187)

JNK
(pThr183/pTyr185)

NF-kB
(pSer536)

Control

76.4 ± 16.9

154.5 ± 34.2

839.7 ± 248.9

50.9 ± 10.5

15.0 ± 1.5

1

112.6 ± 12.0

329.9 ± 48.4 *↑

4650.1 ± 509.0 *↑

239.9 ± 23.9 *↑

2

132.4 ± 17.9

610.0 ± 113.0 *↑

5074.6 ± 770.1 *↑

5

100.9 ± 11.7

202.1 ± 26.3

1880.4 ± 81.7 *↑

p38
(pThr180/pTyr182)

p70S6K
(pThr389/412)

STAT3
(pSer727)

STAT5
(pTyr694/699)

567.7 ± 266.6

39.9 ± 7.2

70.7 ± 18.3

44.2 ± 10.2

18.6 ± 1.5

2349.9 ± 755.5

51.7 ± 4.8

163.0 ± 20.7 *↑

115.4 ± 28.3

559.2 ± 31.5 *↑

18.2 ± 2.1

2795.4 ± 572.0 *↑

56.9 ± 9.9

272.3 ± 50.5 *↑

179.2 ± 12.6 *↑

83.1 ± 8.3 *↑

17.1 ± 0.8

1245.9 ± 342.8

70.6 ± 9.2 *↑

123.4 ± 8.3 *↑

75.7 ± 2.7 *↑

9

88.8 ± 10.7

339.8 ± 53.3 *↑

3276.9 ± 700.0 *↑

117.9 ± 15.1 *↑

13.9 ± 1.2

657.1 ± 287.5

38.8 ± 7.4

151.5 ± 28.7

69.6 ± 15.6

10

142.1 ± 9.5 *↑

584.8 ± 105.5 *↑

1864.9 ± 149.5 *↑

157.2 ± 15.4 *↑

15.4 ± 0.5

1783.6 ± 181.9 *↑

53.4 ± 4.0

178.9 ± 13.4 *↑

115.2 ± 16.9 *↑

PPA

123.5 ± 4.9 *↑

291.0 ± 32.8 *↑

995.4 ± 46.5

132.8 ± 9.1 *↑

19.3 ± 3.0

1459.1 ± 117.6 *↑

46.1 ± 2.9

128.8 ± 2.4 *↑

82.5 ± 3.5 *↑

Note: *—differences in the group are significant (p < 0.05) in comparison to the data of baseline studies (ANOVA); ↑—the indicator significantly increases.
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The fluorescence intensity of the active forms ERK1, JNK, and p38 increased by
1.5–3 times under the action of 1, 2, and 9, i.e., substances with the greatest cytotoxic effect
(Figure 3). Compound 2 exhibited the maximum degree of activation. These pathways were
only slightly activated under the action of 5, 10, and PPA, which showed a significantly
lower cytotoxic effect on tumor cultures.

Figure 3. Box and Whisker Plot of the fluorescence intensity of the ERK 1/2 (pThr185/pTyr187) active
form. A431 epidermoid carcinoma cells were treated with 10 µM compounds 1, 2, 5, 9, 10, or PPA
for 1 h. Cell lysates were analyzed by MILLIPLEX MAP Multi-Pathway Magnetic Bead 9-Plex kit
(48–680 MAG, Merck) using a Bio-Rad 200 analyzer. Statistical analysis was performed using one-way
ANOVA (Bio-Plex Data Pro™ Software). The differences were considered statistically significant at
p < 0.05.

All compounds, with the exception of 2, did not significantly affect the activation of
the transcription factors STAT5A/B (pTyr694/699) and STAT3 (pSer727). Compound 2
slightly activated these proteins, probably through the strong activation of the ERK1, JNK,
and p38 proteins [30].
The set of activated kinase cascades suggests that oxidative stress is the main mechanism of the toxic action of PPA derivatives, leading to cell death [31–33]. In further work,
it would be expedient to evaluate the markers of oxidative stress under the action of PPA
derivatives and the kinetics of their activation on various cell lines.
3. Materials and Methods
3.1. Chemistry
The 1H NMR spectra were acquired on a Bruker AVANCE III 400 MHz NMR spectrometer in CDCl3 . Optical rotations were acquired on an Optical Activity Polaar 3005
Polarimeter using a 2.5 cm cell with an Na 589 nm filter and the concentration of the
samples was denoted as c. The mass spectra data were acquired on a Thermo Scientific
TSQ Quantum Access Max Mass spectrometer. High-resolution mass spectra (HRMS) were
acquired on a LTQ OrbitrapVelos spectrometer and on a Bruker MicrOTOF. FTIR spectra
were acquired on a Shimadzu IR Affinity-1 spectrometer. Organic solvents used were dried
by standard methods when necessary. Commercially available reagents were used without
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further purification. All reactions were monitored by TLC with EMD/Merck KGaA silica
gel-coated plates, with visualization by UV light and by charring with 0.1% ninhydrin in
EtOH. Column chromatography was performed using Merck 60 Å 70-230 mesh silica gel.
The optical density was determined using a Multiskan FC spectrophotometer (Thermo
Scientific, Waltham, MA, USA) at a wavelength of 540 nm when using the MTT assay.
General Procedure for the Synthesis of Compounds 2–9
A mixture of the crude (2S,3S,4S)-3-hydroxy-6-methoxy-3-methyl-7-methylene-5-oxo-2pentyl-2,3,4,5,6,7-hexahydropyrano[2,3-c]pyrrol-4-yl methane sulfonate (1 mmol), the corresponding secondary amine (1.5 mmol), and triethylamine (3 mmol) was stirred in dry
acetonitrile (2 mL) at room temperature until the consumption of the starting material was
complete as judged by TLC analysis (24 h). The reaction mixture was quenched with water
and extracted with EtOAc (2 × 20 mL). The organic extract was washed with brine, dried
over magnesium sulfate, and concentrated in vacuo. The crude product was purified by
flash chromatography (DCM/methanol).
(2S,3R,4R)-4-(dimethylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (2). Yield 45%, yellow oil. −158.11 (c 1.11,
CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.26 (br s, 1H), 5.03 (d, J = 1.5 Hz, 1H), 4.99
(d, J = 1.5 Hz, 1H), 3.93 (s, 3H), 3.65–3.63 (m, 1H), 3.00 (s, 1H), 2.44 (br s, 6H), 2.00–1.91 (m,
1H), 1.69–1.53 (m, 2H), 1.44–1.31 (m, 5H), 1.04 (s, 3H), 0.91 (t, J = 6.7 Hz, 3H). 13C NMR
(101 MHz, CDCl3 ) δ 167.18 (s), 158.35 (s), 137.11 (s), 101.74 (s), 91.58 (s), 83.24 (s), 68.47 (s),
64.58 (s), 62.74 (s), 31.86 (s), 28.42 (s), 26.59 (s), 22.69 (s), 20.18 (s), 14.19 (s). IR (KBr) 3430,
2955, 2930, 2859, 1723, 1635, 1436, 1370, 1265, 1149, 986, 775 cm−1 . HRMS [M + H]+calcd
for C17 H29 N2 O4 325.21218, found 325.21206.
(2S,3R,4R)-4-(diethylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (3). Yield 50%, yellow oil. −182.36 (c 1.15,
CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.23 (s, 1H), 5.03 (d, J = 1.5 Hz, 1H), 4.98 (d,
J = 1.5 Hz, 1H), 3.93 (s, 3H), 3.56–3.54 (m, 1H), 3.15 (s, 1H), 3.06–2.27 (m, 4H), 2.02–1.92 (m,
1H), 1.72–1.54 (m, 2H), 1.49–1.30 (m, 5H), 1.09 (br s, 6H), 1.05 (s, 3H), 0.92 (t, J = 6.8 Hz, 3H).
13C NMR (101 MHz, CDCl3 ) δ 167.05 (s), 158.53 (s), 137.16 (s), 102.33 (s), 91.43 (s), 83.26
(s), 67.93 (s), 64.52 (s), 60.14 (s), 48.97 (s), 45.76 (s), 31.85 (s), 28.49 (s), 26.62 (s), 22.69 (s),
19.98 (s), 14.20 (s). IR (KBr) 3207, 2961, 2932, 2860, 1723, 1635, 1468, 1379, 1268, 1149, 978,
764 cm−1 . HRMS [M + H]+calcd for C19 H33 N2 O4 353.24348, found 353.24324.
(2S,3R,4R)-4-(dipropylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (4). Yield 40%, yellow oil. −205.07 (c 2.01,
CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.27 (s, 1H), 5.03 (d, J = 1.4 Hz, 1H), 4.99 (d,
J = 1.4 Hz, 1H), 3.93 (s, 3H), 3.58 (m, 1H), 3.14 (s, 1H), 2.98 (br s, 1H), 2.46 (m, 3H), 1.98–1.90
(m, 1H), 1.64–1.34 (m, 11H), 1.04 (s, 3H), 0.92–0.89 (m, 9H). 13C NMR (101 MHz, CDCl3 ) δ
167.08 (s), 158.51 (s), 137.19 (s), 102.36 (s), 91.48 (s), 83.27 (s), 83.17 (s), 68.20 (s), 64.53 (s),
61.00 (s), 58.02 (s), 54.07 (s), 31.76 (s), 28.40 (s), 26.45 (s), 22.67 (s), 22.28 (s), 21.88 (s), 20.16
(s), 14.19 (s), 11.90 (s). IR (KBr) 3464, 2960, 2932, 2873, 1724, 1635, 1436, 1378, 1149, 1072,
914 cm−1 . HRMS [M + H]+calcd for C21 H37 N2 O4 381.27478, found 381.27435.
(2S,3R,4R)-4-(dibutylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (5). Yield 39%, yellow oil. −178.71 (c 1.8, CH2 Cl2 ).
1H NMR (400 MHz, CDCl3 ) δ 5.28 (s, 1H), 5.03 (d, J = 1.5 Hz, 1H), 4.99 (d, J = 1.5 Hz, 1H),
3.93 (s, 3H), 3.59–3.57 (m, 1H), 3.14 (s, 1H), 2.99 (br s, 1H), 2.70–2.26 (m, 3H), 1.99–1.91 (m,
1H), 1.67–1.31 (m, 15H), 1.05 (s, 3H), 1.05–0.90 (m, 9H). 13C NMR (101 MHz, CDCl3 ) δ
167.12 (s), 158.53 (s), 137.20 (s), 102.37 (s), 91.59 (s), 91.47 (s), 83.30 (s), 83.20 (s), 68.15 (s),
64.61 (s), 64.54 (s), 60.99 (s), 60.94 (s), 31.76 (s), 28.41 (s), 26.57 (s), 22.68 (s), 20.63 (s), 20.18 (s),
14.24 (s). IR (KBr) 3437, 2958, 2931, 2860, 1724, 1634, 1435, 1378, 1150, 1076, 1033, 914 cm−1 .
HRMS [M + H]+calcd for C23 H41 N2 O4 409.30608, found 409.30580.
(2S,3R,4R)-4-(dipentylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (6). Yield 40%, yellow oil. −179.86 (c 1.45,
CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.29 (s, 1H), 5.03 (d, J = 1.4 Hz, 1H), 4.99 (d,
J = 1.4 Hz, 1H), 3.93 (s, 3H), 3.59–3.57 (m, 1H), 3.14 (s, 1H), 2.99 (br s, 1H), 2.70–2.22 (m, 3H),
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2.00–1.91 (m, 1H), 1.62–1.25 (m, 19H), 1.05 (s, 3H), 0.93–0.89 (m, 9H). 13C NMR (101 MHz,
CDCl3 ) δ 167.10 (s), 158.51 (s), 137.19 (s), 102.37 (s), 91.46 (s), 83.27 (s), 83.16 (s), 68.15 (s),
64.53 (s), 60.98 (s), 60.92 (s), 55.98 (s), 52.11 (s), 31.73 (s), 29.62 (s), 29.00 (s), 28.41 (s), 26.54
(s), 22.76 (s), 22.68 (s), 20.18 (s), 14.19 (s). IR (KBr) 3485, 2957, 2930, 2860, 2072, 1724, 1634,
1436, 1378, 1150, 1079, 915 cm−1 . HRMS [M + H]+calcd for C25 H45 N2 O4 437.33738, found
437.33701.
(2S,3R,4R)-4-(dihexylamino)-3-hydroxy-6-methoxy-3-methyl-7-methylene-2-pentyl-3,4,6,7tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (7). Yield 41%, yellow oil. −185.98 (c 0.97,
CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.28 (s, 1H), 5.03 (d, J = 1.4 Hz, 1H), 4.98 (d,
J = 1.4 Hz, 1H), 3.93 (s, 3H), 3.60–3.57 (m, 1H), 3.13 (s, 1H), 2.98 (br s, 1H), 2.67–2.29 (m, 3H),
1.99–1.91 (m, 1H), 1.65–1.29 (m, 23H), 1.04 (s, 3H), 0.93–0.86 (m, 9H). 13C NMR (101 MHz,
CDCl3 ) δ 167.11 (s), 158.51 (s), 137.20 (s), 102.39 (s), 91.44 (s), 83.30 (s), 83.20(s), 68.15 (s),
64.61 (s), 64.53 (s), 60.99 (s), 60.94 (s), 56.15 (s), 52.34 (s), 31.91 (s), 31.75 (s), 29.28 (s), 28.80
(s), 28.42 (s), 27.12 (s), 26.57 (s), 22.77 (s), 22.69 (s), 20.18 (s), 14.18 (s). IR (KBr) 3474, 2957,
2929, 2858, 2075, 1724, 1634, 1435, 1378, 1151, 1081, 914 cm−1 . HRMS [M + H]+calcd for
C27 H49 N2 O4 465.36868, found 465.36853.
(2S,3R,4R)-3-hydroxy-4-[(2-hydroxyethyl)(methyl)amino]-6-methoxy-3-methyl-7-methylene-2pentyl-3,4,6,7-tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (8). Yield 63%, yellow oil. −151.76
(c 2.1, CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.10 (d, J = 1.7 Hz, 1H), 5.05 (d, J = 1.6 Hz,
1H), 4.82 (br s, 1H), 4.01–3.95 (m, 4H), 3.65–3.62 (m, 2H), 3.50 (s, 1H), 3.09–2.90 (m, 2H), 2.42
(s, 3H), 2.02–1.93 (m, 1H), 1.69–1.57 (m, 2H), 1.44–1.33 (m, 5H), 1.06 (s, 3H), 0.92 (t, J = 6.8
Hz, 3H). 13C NMR (101 MHz, CDCl3 ) δ 167.72 (s), 158.61 (s), 136.70 (s), 101.63 (s), 92.74 (s),
83.18 (s), 69.57 (s), 64.76 (s), 61.20 (s), 59.22 (s), 39.75 (s), 32.06 (s), 31.83 (s), 29.84 (s), 28.23
(s), 26.54 (s), 22.68 (s), 19.75 (s), 14.17 (s). IR (KBr) 3420, 2956, 2929, 2859, 1719, 1635, 1438,
1378, 1193, 1081, 1021, 951, 913 cm−1 . HRMS [M + H]+calcd for C19 H30 N2 O5 355.22275,
found 355.22267.
(2S,3R,4R)-4-[ethyl(2-hydroxyethyl)amino]-3-hydroxy-6-methoxy-3-methyl-7-methylene-2pentyl-3,4,6,7-tetrahydropyrano[2,3-c]pyrrol-5(2H)-one (9). Yield 45%, yellow oil. −197.38
(c 1.91, CH2 Cl2 ). 1H NMR (400 MHz, CDCl3 ) δ 5.10 (s, 1H), 5.05 (s, 1H), 4.71 (br s, 1H),
3.94 (br s, 4H), 3.62–3.59 (m, 1H), 3.19–2.52 (m, 4H), 2.02–1.90 (m, 1H), 1.69–1.55 (m, 4H),
1.45–1.32 (m, 5H), 1.07 (br s, 6H), 0.91 (t, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3 ) δ
167.70 (s), 158.60 (s), 136.76 (s), 102.19 (s), 92.59 (s), 83.07 (s), 69.10 (s), 64.70 (s), 60.78 (s),
59.36 (s), 55.50 (s), 50.96 (s), 31.81 (s), 28.25 (s), 26.56 (s), 22.67 (s), 19.72 (s), 14.39 (s), 14.19
(s). IR (KBr) 3430, 2958, 2931, 2860, 1720, 1634, 1438, 1438, 1379, 1336, 1151, 1054, 990, 913,
743 cm−1 . HRMS [M + H]+calcd for C19 H33 N2 O5 369.23840, found 369.23828.
3.2. Biological Assay Methods
3.2.1. Assessment of the Level of Compounds Cytotoxicity in a Panel of Tumor
Cell Cultures
Tumor Cell Cultures
Cell cultures used in the work: adhesive cultures HBL-100 cells (cells of a normal mammary gland epithelium, immortalized by the SV40 virus and acquired tumorigenicity [34]);
MCF-7 breast cancer cells; PC-3 prostate adenocarcinoma cells; HCT-116 colorectal cancer
cells; non-small cell lung cancer cells A549; human embryonic kidney cells HEK293; suspension cultures (NCI-H929 and RPMI8226 multiple myeloma cells), K562 chronic myeloid
leukemia cells; THP-1 acute monocytic leukemia cells; and Jurkat acute T-cell leukemia
cells. We also used several primary cultures of soft tissue sarcomas at 3–4passeges, kindly
provided by T.I. Fetisov (The Ethics Committee of N.N. Blokhin NMRCO, protocol code
18-28-09095 and date of approval 28 September 2018) [35].
Modifications of cell lines: K562/i-S9 is a clone obtained after transfection of K562
cells with the ABCB1 (MDR1) gene-encoding P-glycoprotein [36]. Cells HBL-100/Dox and
K562/i-S9_Dox are cells obtained by long-term selection with increasing concentrations
of doxorubicin (Sigma-Aldrich, St. Louis, MO, USA) from HBL-100 and K562/i-S9 cells,
respectively. MCF-7, A594 cells, and primary cultures of soft tissue sarcomas were cultured
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in DMEM medium (PanEko, Russia), PC-3 and HCT-116 cells and all suspension cultures
in RPMI1640 medium (PanEko, Russia) supplemented with 10% fetal bovine serum (GE
Healthcare LifeSciences, USA), and gentamicin at a concentration of 40 µg/mL at 37 ◦ C
and 5% CO2 .
MTT Test
Cells MCF-7, PC-3, A549, and HCT-116, and primary cultures of STSwere seeded in
96-well plates, 6 × 103 cells per well in 90 µL of culture medium. Suspension cultures
were seeded at a concentration of 25 × 103 cells per well in 135 µL of medium. The
test substances were dissolved in DMSO (Applichem, Council Bluffs, IA, USA) until a
concentration of 1 × 10− 2 M was obtained; for the subsequent dilution of the substances, a
serum-free culture medium was used. The next day, for adhesive cultures, and on the same
day, for suspension cultures, substances were added to the plates in a volume of 10 µL
(adhesive cultures) and 15 µL (suspension cultures) per well at various concentrations;
each concentration was added in 3–4 repetitions. The cells were cultured in the presence
of substances for 48 h. Then, MTT reagent (PanEko, Moscow, Russia) was added to the
wells at a concentration of 5 mg/mL in a volume of 20 µL per well. After 1.5–2 h, the
medium with the reagent was removed, and the precipitate of the crystals of formazan was
dissolved in 60 µL of DMSO. The optical density was determined using a Multiskan FC
spectrophotometer (Thermo Scientific, Waltham, MA, USA) at a wavelength of 540 nm.
Based on the results of the experiments, a schedule was plotted of the dependence
of the percentage of surviving cells (from control) on the concentration of the compound,
and the sought concentration IC50 was calculated. The experiments were carried out in
3–4 times.
Flow Cytometry
To assess the expression of P-gp in K562, K562/i-S9, and K562/i-S9_Dox cells, 5 × 105
cells were fixed in 4% formaldehyde solution, then washed twice in PBS, after 30 min
they were incubated with monoclonal antibody FITC Mouse Anti-Human P-glycoprotein,
clone 17F9 (BD Biosciences, San Jose, CA, USA) was washed twice to remove antibodies in
PBS. The number of luminous cells was analyzed using a Becton Dickinson FACScan flow
cytometer. The results were analyzed using Diva and CyFlodgic software.
Evaluation of the Release of Rhodamine 123 (Rd123) from Cells with an Overexpression of
P-Glycoprotein
To assess the interaction of the investigated compounds with P-gp, we used the test
for the release of rhodamine 123 (Rd123) (Sigma-Aldrich, St. Louis, MO, USA) from cells
with P-gp overexpression K562/i-S9_Dox. The principle of the test is as follows: Rd123
is a fluorophore and a known P-gp substrate. During incubation, Rd123 enters the cells
by simple diffusion, and then Rd123 begins to interact with P-gp, which releases it from
the cell. Cells in which Rd123 is present are stained and can be detected by flow cytometry.
The more efficiently P-gp works, the less stained cells in the population remain over time.
If inhibitors or modulators of P-gp activity are added to the cells, then the cells remain
stained; if substances do not interact with P-gp, then the cell population loses its luminosity.
The experiment used K562/i-S9_Dox cells with P-gp overexpression. Cells (5 × 105 per
point) were incubated with Rd123 at a concentration of 3.5 µg/mL for 20 min in serum-free
RPMI1640 medium. Furthermore, the efficiency of Rd123 entry into cells was assessed.
Subsequently, the cells were washed once from Rd123 in a PBS solution, and the precipitate
was divided into several parts; the cells were placed in a clean serum-free medium to assess
the efficiency of Rd123 release, as well as in a serum-free medium with the addition of the
following compounds at a concentration of 20 µM: verapamil (a classic inhibitor of P-gp)
and test compounds 1, 2, and 9. Incubation with substances took place for 35 min in 1 mL
of serum-free medium. Then, the cells were precipitated, washed with PBS solution, and
the % of stained cells in the population were assessed on a flow cytometer.
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Statistical Analysis
The results were presented as the mean ± SD. GraphPad Prism 6.0 was used for
statistical analysis. The statistical significance was evaluated by unpaired t-test.
3.2.2. Evaluation of the Effect of Phaeosphaeride A Derivatives on Key Signaling Pathways
To determine the integral cellular response using the xCelligence RTCA equipment
(AceaBioscience, Santa Clara, CA, USA), 20 thousand cells were inoculated into a well of a
specialized plate allowing the determination of the cell index in real time and cultured in
complete growth medium. The next day after the seeding, the medium was replaced with
an experimental one (compounds at concentrations of 50, 20, 10, 5, 2, 1, and 0.5 µm). The
cell index was monitored for 3 days after the addition of the xenobiotic. The concentration
closest to the IC50 (10 µM) was chosen as the experimental concentration.
We used a MILLIPLEX MAP Multi-Pathway Magnetic Bead 9-Plex-Cell Signaling
Multiplex Assay kit (Merck/Millipore), according to the manufacturer’s protocol. A431
cells were cultured in DMEM with 10% FBS in 24-well plates. Compounds were added
to the subconfluent cells at a concentration of 10 µM in DMEM medium for 1 h. Each
compound was added in 5 experimental repeats. Cell lysates were prepared with lysis
buffer (Millipore) with protease inhibitors (Complete, Roche); the protein concentration
in the lysates was determined by the Lowry method. In samples equalized in protein
concentration, the active forms of kinase cascades were determined using a Bio-Plex 200
fluorescent analyzer (Bio-Rad).
4. Conclusions
Thus, the obtained PPA derivatives can overcome the drug resistance of tumor cells
associated with the overexpression of P-glycoprotein by modulating the work of this
transporter, which makes them promising in terms of creating new anticancer drugs aimed
at treating resistant malignant neoplasms. A potential mechanism of the toxic effect of
PPA derivatives associated with oxidative stress has also been identified. In addition, the
effective two-stage synthesis of the presented compounds based on natural substances
makes the development of this project even more attractive.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/ph15040395/s1, Copies of 1H, 13C, ROESY NMR spectra, HRMS
for compounds 2–9 (Figures S1–S25), markers of key signaling pathways for compounds 1, 2, 5, 9, 10,
PPA (Figures S26–S34).
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